Do analysts recommend BIVI or CRDF?

Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 594.44%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardiff Oncology 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Is BIVI or CRDF more profitable?

BioVie has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Cardiff Oncology's return on equity of -103.10% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% Cardiff Oncology -7,885.43% -103.10% -75.52%

Does the media prefer BIVI or CRDF?

In the previous week, BioVie had 6 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for BioVie and 2 mentions for Cardiff Oncology. BioVie's average media sentiment score of 0.86 beat Cardiff Oncology's score of 0.00 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BIVI or OKYO?

OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 265.59%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has higher earnings & valuation, BIVI or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is BIVI or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% OKYO Pharma N/A N/A N/A

Does the media refer more to BIVI or OKYO?

In the previous week, BioVie had 7 more articles in the media than OKYO Pharma. MarketBeat recorded 8 mentions for BioVie and 1 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.89 beat BioVie's score of 0.86 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OKYO Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate BIVI or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, BIVI or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A

Is BIVI or TELO more profitable?

Telomir Pharmaceuticals' return on equity of -102.70% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% Telomir Pharmaceuticals N/A -102.70% -90.75%

Do analysts rate GANX or BIVI?

Gain Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 312.09%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Gain Therapeutics is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GANX or BIVI more profitable?

BioVie's return on equity of -126.02% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% BioVie N/A -126.02% -108.88%

Does the media favor GANX or BIVI?

In the previous week, Gain Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 9 mentions for Gain Therapeutics and 8 mentions for BioVie. BioVie's average media sentiment score of 0.86 beat Gain Therapeutics' score of 0.27 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioVie 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VBIO or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VBIO or BIVI more profitable?

BioVie's return on equity of -126.02% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Valion Bio, Inc. Common Stock N/A -193.17% -67.10% BioVie N/A -126.02% -108.88%

Does the media prefer VBIO or BIVI?

In the previous week, BioVie had 5 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 8 mentions for BioVie and 3 mentions for Valion Bio, Inc. Common Stock. BioVie's average media sentiment score of 0.86 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioVie 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioVie (BIVI) Competitors

$2.03 0.00 (0.00%)

As of 04:00 PM Eastern

Compare

BIVI vs. CRDF, OKYO, TELO, GANX, and VBIO

Should you buy BioVie stock or one of its competitors? BioVie's main competitors and comparable companies include Cardiff Oncology (CRDF), OKYO Pharma (OKYO), Telomir Pharmaceuticals (TELO), Gain Therapeutics (GANX), and Valion Bio, Inc. Common Stock (VBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioVie compare to Cardiff Oncology?

BioVie (NASDAQ:BIVI) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 594.44%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

BioVie has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

BioVie has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Cardiff Oncology's return on equity of -103.10% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

4.6% of BioVie shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Comparatively, 8.8% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioVie had 6 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for BioVie and 2 mentions for Cardiff Oncology. BioVie's average media sentiment score of 0.86 beat Cardiff Oncology's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioVie has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Cardiff Oncology	$590K	142.40	-$45.85M	-$0.60	N/A

Summary

Cardiff Oncology beats BioVie on 10 of the 15 factors compared between the two stocks.

How does BioVie compare to OKYO Pharma?

BioVie (NASDAQ:BIVI) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

BioVie has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market.

4.6% of BioVie shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

OKYO Pharma's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
OKYO Pharma	N/A	N/A	N/A

In the previous week, BioVie had 7 more articles in the media than OKYO Pharma. MarketBeat recorded 8 mentions for BioVie and 1 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.89 beat BioVie's score of 0.86 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OKYO Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 265.59%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

OKYO Pharma beats BioVie on 8 of the 11 factors compared between the two stocks.

How does BioVie compare to Telomir Pharmaceuticals?

BioVie (NASDAQ:BIVI) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

BioVie has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

4.6% of BioVie shares are owned by institutional investors. 0.9% of BioVie shares are owned by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals' return on equity of -102.70% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BioVie had 8 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 8 mentions for BioVie and 0 mentions for Telomir Pharmaceuticals. BioVie's average media sentiment score of 0.86 beat Telomir Pharmaceuticals' score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Positive
Telomir Pharmaceuticals	Neutral

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Summary

Telomir Pharmaceuticals beats BioVie on 7 of the 12 factors compared between the two stocks.

How does BioVie compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Gain Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, BioVie has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 0.9% of BioVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioVie's return on equity of -126.02% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
BioVie	N/A	-126.02%	-108.88%

Gain Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 312.09%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Gain Therapeutics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gain Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 9 mentions for Gain Therapeutics and 8 mentions for BioVie. BioVie's average media sentiment score of 0.86 beat Gain Therapeutics' score of 0.27 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioVie	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics has higher revenue and earnings than BioVie. Gain Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A

Summary

Gain Therapeutics beats BioVie on 9 of the 14 factors compared between the two stocks.

How does BioVie compare to Valion Bio, Inc. Common Stock?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Valion Bio, Inc. Common Stock has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, BioVie has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

BioVie's return on equity of -126.02% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
BioVie	N/A	-126.02%	-108.88%

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Comparatively, 0.9% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BioVie had 5 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 8 mentions for BioVie and 3 mentions for Valion Bio, Inc. Common Stock. BioVie's average media sentiment score of 0.86 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioVie	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valion Bio, Inc. Common Stock has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Valion Bio, Inc. Common Stock beats BioVie on 6 of the 11 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIVI vs. The Competition

Export

Metric	BioVie	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.16M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.64	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.66	16.29	12.89	6.14
Net Income	-$22.07M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-7.31%	-1.37%	-0.33%	-1.47%
1 Month Performance	25.31%	11.07%	6.51%	2.47%
1 Year Performance	21.56%	53.71%	25.19%	15.84%

BioVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIVI BioVie	0.9702 of 5 stars	$2.03 flat	N/A	+28.5%	$17.16M	N/A	N/A	10	Short Interest Increase
CRDF Cardiff Oncology	1.9631 of 5 stars	$1.04 +5.0%	$7.50 +619.1%	-45.6%	$80.51M	$590K	N/A	20
OKYO OKYO Pharma	3.1393 of 5 stars	$1.53 +0.3%	$5.67 +271.6%	-30.2%	$80.03M	N/A	N/A	7	Positive News Short Interest Decrease
TELO Telomir Pharmaceuticals	0.4096 of 5 stars	$1.14 +1.8%	N/A	-6.7%	$78.41M	N/A	N/A	1
GANX Gain Therapeutics	2.4286 of 5 stars	$1.78 -0.9%	$7.50 +320.4%	-6.3%	$77.46M	$50K	N/A	20	News Coverage Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIVI) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioVie (BIVI) Competitors

BIVI vs. CRDF, OKYO, TELO, GANX, and VBIO

How does BioVie compare to Cardiff Oncology?

Summary

How does BioVie compare to OKYO Pharma?

Summary

How does BioVie compare to Telomir Pharmaceuticals?

Summary

How does BioVie compare to Gain Therapeutics?

Summary

How does BioVie compare to Valion Bio, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioVie (BIVI) Competitors

BIVI vs. CRDF, OKYO, TELO, GANX, and VBIO

How does BioVie compare to Cardiff Oncology?

Do analysts recommend BIVI or CRDF?

Which has more volatility and risk, BIVI or CRDF?

Is BIVI or CRDF more profitable?

Do institutionals & insiders have more ownership in BIVI or CRDF?

Does the media prefer BIVI or CRDF?

Which has higher valuation & earnings, BIVI or CRDF?

Summary

How does BioVie compare to OKYO Pharma?

Which has higher earnings & valuation, BIVI or OKYO?

Which has more risk and volatility, BIVI or OKYO?

Do insiders and institutionals hold more shares of BIVI or OKYO?

Is BIVI or OKYO more profitable?

Does the media refer more to BIVI or OKYO?

Do analysts recommend BIVI or OKYO?

Summary

How does BioVie compare to Telomir Pharmaceuticals?

Which has more volatility and risk, BIVI or TELO?

Do insiders and institutionals hold more shares of BIVI or TELO?

Is BIVI or TELO more profitable?

Do analysts rate BIVI or TELO?

Does the media refer more to BIVI or TELO?

Which has preferable earnings & valuation, BIVI or TELO?

Summary

How does BioVie compare to Gain Therapeutics?

Which has more volatility and risk, GANX or BIVI?

Do insiders and institutionals have more ownership in GANX or BIVI?

Is GANX or BIVI more profitable?

Do analysts rate GANX or BIVI?

Does the media favor GANX or BIVI?

Which has better valuation and earnings, GANX or BIVI?

Summary

How does BioVie compare to Valion Bio, Inc. Common Stock?

Which has more volatility and risk, VBIO or BIVI?

Is VBIO or BIVI more profitable?

Do institutionals and insiders hold more shares of VBIO or BIVI?

Does the media prefer VBIO or BIVI?

Which has higher earnings & valuation, VBIO or BIVI?

Do analysts prefer VBIO or BIVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools